Beam Historical Valuation

BEAM Stock  USD 27.20  1.36  5.26%   
Some fundamental drivers such as market cap or Beam Therapeutics enterprice value can be analyzed from historical perspective to project value of the company into the future. Some investors analyze Beam Therapeutics valuation indicators such as Working Capital of 0.0 or Enterprise Value of 3.5 B to time the market or to short-sell their positions based on the trend in valuation ratios. It is a perfect tool to project the direction of Beam Therapeutics's future value.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.

About Beam Valuation Data Analysis

Valuation is the financial process of determining what Beam Therapeutics is worth. Beam Therapeutics valuation ratios put that insight into the context of a company's share price, where they serve as useful tools for evaluating and utilizing investment potential. Beam Therapeutics valuation ratios help investors to determine whether Beam Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Beam with respect to the benefits of owning Beam Therapeutics security.

Beam Therapeutics Valuation Data Chart

As of the 28th of November 2024, Market Cap is likely to grow to about 3.8 B. Also, Enterprise Value is likely to grow to about 3.5 B

Enterprise Value

Enterprise Value (or EV) is usually referred to as Beam Therapeutics theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Beam Therapeutics debt, but would also pocket its cash. Enterprise Value is more accurate representation of Beam Therapeutics value than its market capitalization because it takes into account all of Beam Therapeutics existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Beam Therapeutics is a strong investment it is important to analyze Beam Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Beam Therapeutics' future performance. For an informed investment choice regarding Beam Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.58)
Revenue Per Share
4.273
Quarterly Revenue Growth
(0.17)
Return On Assets
(0.09)
Return On Equity
(0.18)
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.